PO.CL05.02 · 临床研究

溶瘤病毒感染的肿瘤驱动 NK 细胞中的 AP-1 和 IRF 信号传导以维持抗肿瘤活性

Oncolytic virus infected tumors drive AP-1 and IRF signaling in NK cells to sustain anti tumor activity

海报缩略图:溶瘤病毒感染的肿瘤驱动 NK 细胞中的 AP-1 和 IRF 信号传导以维持抗肿瘤活性
编号 5194 展板 12 时间 4/21 09:00–12:00 区域 Section 40 主讲 Hila Shaim, MD
分会场 Adoptive Cell Therapy 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Hila Shaim1, Cheryl Jiang1, Mayra Shanley1, Hind Rafei1, Jiajinlong Kang1, Yu-Sung Hsu1, Huihui Fan1, Patrick Zhang1, Rafet Basar1, May Daher1, Qingnan Liang1, Donghai Xiong1, Joy Gumin1, Viswakalyan Kotapali1, Corry Jones1, April Gilbert1, Luis Muniz-Feliciano1, Gary M. Deyter1, Pinaki Banerjee1, Madison Moore1, Ye Ethan Li1, Dexing Fang1, Sunil Acharya1, Inci Biederstädt1, Hong Jiang1, Nadima Uprety1, Rejeena Shrestha1, Byron Jia1, Alexander Biederstadt1, Paul Daniel1, Maliha Munir1, Mecit Kaplan1, Mayela Mendt1, Oluwatosin Banjo1, Vakul Mohanty1, Jinzhuang Dou1, Xianli Jiang1, Elizabeth Shpall1, Ken Chen2, Abhinav Jain3, Frederick F. Lang1, Candelaria Gomez-Manzano1, Juan Fueyo1, Katayoun Rezvani1

1UT MD Anderson Cancer Center, Houston, TX,2Asst. Professor, Dept. of Bioinformatics & Computational Bio., UT MD Anderson Cancer Center, Houston, TX,3Dept. of Biochem. & Molec. Biology, UT MD Anderson Cancer Center, Houston, TX

摘要 Abstract

中文摘要
背景:自然杀伤(NK)细胞在癌症免疫监视中发挥着关键作用。它们浸润肿瘤微环境,通过整合来自癌细胞上应激诱导配体的激活信号与由主要组织相容性免疫复合物(HLA)介导、维持自身耐受的抑制信号来杀伤肿瘤细胞。然而,其对实体瘤的有效性受到肿瘤驱动的免疫抑制的限制。溶瘤病毒(OV)可通过选择性感染肿瘤细胞并刺激抗肿瘤免疫,潜在地克服这一障碍。因此我们将溶瘤腺病毒 Delta24-RGD 与 NK 细胞联合以靶向侵袭性实体瘤,旨在阐明病毒诱导 NK 细胞过度激活的机制,并支持该方法的临床转化。 方法:我们开展了体外和体内研究,以评估离体扩增的脐带血来源 NK 细胞对 Delta24-RGD 感染的胰腺导管腺癌和胶质母细胞瘤细胞的细胞毒性。体外将 OV 感染的肿瘤细胞与 NK 细胞共培养,随后进行 CyTOF 表型分析,并使用 xCelligence 和 Incucyte 评估细胞毒性。通过首先将 NK 细胞与 OV 感染或未感染的肿瘤细胞共培养、分离 NK 细胞、然后测试其对新鲜肿瘤靶标的连续杀伤能力,评估长期细胞毒性能力。使用患者来源异种移植胶质母细胞瘤小鼠模型测试体内疗效。机制研究包括 ATAC-seq、bulk RNA-seq、CUT&RUN 以及 JUNB 和 FOS 的 CRISPR-Cas9 敲除。 结果:NK 细胞对 OV 感染的 PDAC 和胶质母细胞瘤细胞表现出协同细胞毒性,并获得了增强的激活表型,DNAM-1、NKG2D、CD94、NKp30、CD25、CD69、ICOS、T-bet、TRAIL 和 CD107a 的表达增加。OV 感染的肿瘤细胞上调应激配体,包括 B7-H6、MICA/B 和 ULBP1,并下调 HLA-I。在体内,联合疗法显著减少了胶质母细胞瘤模型中的肿瘤生长并延长了生存期。NK 细胞过度激活需要与 OV 感染的肿瘤细胞直接接触,可能由病毒介导的肿瘤细胞上 NK 配体表达调节所驱动。强力激活的 NK 细胞在反复肿瘤再攻击中维持了增强的细胞毒性,表明存在持久的功能重编程。机制研究揭示了 AP-1 激活随后是 I 型干扰素信号传导。破坏 JUNB 和 FOS 以及化学性 AP-1 抑制均减弱了这一效应。CUT&RUN 证实了支持细胞毒性的 AP-1 依赖性转录程序。 结论:溶瘤病毒通过重编程 AP-1 驱动的转录反应,协同增强了持续的 NK 细胞抗肿瘤活性。这一联合策略为推进基于 NK 细胞的实体瘤疗法提供了机制基础。
查看英文原文 English abstract
Background: Natural killer (NK) cells play a crucial role in cancer immunosurveillance. They infiltrate the tumor microenvironment and kill tumor cells by integrating activating signals from stress-induced ligands on cancer cells and inhibitory signals, mediated by the major histocompatibility immune complex (HLA), that preserve self-tolerance. However, their effectiveness against solid tumors is limited by tumor-driven immune-suppression. Oncolytic viruses (OV) can potentially overcome this barrier by selectively infecting tumor cells and stimulating antitumor immunity. We thus combined the oncolytic adenovirus Delta24-RGD with NK cells to target aggressive solid tumors, aiming to define the mechanisms underlying virus-induced NK cell hyperactivation and supporting clinical translation of this approach. Methods: We conducted in vitro and in vivo studies to evaluate the cytotoxicity of ex vivo-expanded cord blood-derived NK cells against Delta24-RGD-infected pancreatic ductal adenocarcinoma and glioblastoma cells. In vitro, OV-infected tumor cells were co-cultured with NK cells, followed by CyTOF phenotyping and cytotoxicity evaluation using xCelligence and Incucyte. Long-term cytotoxic capacity was assessed by first co-culturing NK cells with OV-infected or non-infected tumor cells, isolating NK cells and then testing their serial killing against fresh tumor targets. In vivo efficacy was tested using patient-derived xenograft glioblastoma mouse models. Mechanistic workup included ATAC-seq, bulk RNA-seq, CUT&RUN, and CRISPR-Cas9 knockout of JUNB and FOS. Results: NK cells exhibited synergistic cytotoxicity against OV-infected PDAC and glioblastoma cells and acquired an enhanced activation phenotype with increased expression of DNAM-1, NKG2D, CD94, NKp30, CD25, CD69, ICOS, T-bet, TRAIL, and CD107a. OV-infected tumor cells upregulated stress ligands including B7-H6, MICA/B, and ULBP1 and downregulated HLA-I. In vivo, the combination therapy significantly reduced tumor growth and extended survival in glioblastoma models. NK hyperactivation required direct contact with OV-infected tumor cells, likely driven by virus-mediated modulation of NK-ligand expression on tumor cells. Robustly activated NK cells maintained enhanced cytotoxicity through repeated tumor rechallenges, indicating durable functional reprogramming. Mechanistic studies revealed AP-1 activation followed by type I interferon signaling. Disruption of JUNB and FOS, as well as chemical AP-1 inhibition reduced this effect. CUT&RUN confirmed AP-1 dependent transcriptional programs supporting cytotoxicity. Conclusion: Oncolytic viruses synergistically enhance sustained NK cell antitumor activity by reprogramming AP-1 driven transcriptional responses. This combination strategy provides a mechanistic foundation for advancing NK cell-based therapies against solid tumors.
利益披露 Disclosure
H. Shaim, None.. C. Jiang, None.. J. Kang, None.. Y. Hsu, None.. H. Fan, None.. R. Basar, None.. Q. Liang, None.. D. Xiong, None.. J. Gumin, None.. V. Kotapali, None.. C. Jones, None.. A. Gilbert, None.. L. Muniz-Feliciano, None.. G. M. Deyter, None.. P. Banerjee, None.. M. Moore, None.. Y. Li, None.. S. Acharya, None.. I. Biederstädt, None.. H. Jiang, None.. N. Uprety, None.. R. Shrestha, None.. B. Jia, None.. A. Biederstadt, None.. P. Daniel, None.. M. Munir, None.. M. Kaplan, None.. M. Mendt, None.. O. Banjo, None.. J. Dou, None.. E. Shpall, None.. C. Gomez-Manzano, None.. J. Fueyo, None.

← 返回 AACR 2026 检索